Updated:
Yantai Dongcheng Pharmaceutical Group Co.
Yantai Dongcheng Pharmaceutical Group Co. is a other based in Yantai, founded 1998; the Altss profile covers its classification, headquarters, registration,...
Yantai Dongcheng Pharmaceutical Group Co.
General information
Firm type
other
Year founded
1998
Location
Region
Asia
Country
China
City
Yantai
Corporate office
Yantai, Shandong, China
Additional offices
Seoul, South Korea · Shanghai, China · Gyeonggi-do, South Korea · Taipei, Taiwan
Principals
Youyu Shouyi (由守谊)
Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at Yantai Dongcheng Pharmaceutical Group?
Chairman Youyu Shouyi, who founded the company in 1998, serves as the ultimate decision-maker. The firm is publicly traded, so strategic capital allocation also involves its board of directors and investor-relations disclosures on the Shenzhen Stock Exchange.
Is Yantai Dongcheng a family office or an operating pharmaceutical company?
It is an operating pharmaceutical company listed on the Shenzhen Stock Exchange, not a family office. The firm does not manage external capital or function as an allocator.
What is the relationship between Yantai Dongcheng and its nuclear medicine subsidiary?
Yantai Dongcheng holds a controlling stake in Lanacheng, a radiopharmaceutical development subsidiary. Lanacheng filed the NDA for fluro-[18F]-seride injection in January 2026, which if approved would add a proprietary imaging agent to the group's portfolio.
Which sectors does Yantai Dongcheng explicitly avoid?
The company does not disclose explicit sector exclusion policies. However, its known business lines focus strictly on pharmaceutical manufacturing and related healthcare products, with no disclosed exposure to financial services or non-healthcare real estate.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: